US: Reckitt Benckiser sales beat estimates on cold remedies | Progresiv
Reckitt Benckiser Group has reported estimate-beating first-quarter revenue growth on better-than-expected sales of flu remedies in the US. Sales rose five per cent, excluding acquisitions, disposals and currency shifts, the UK-based company said in a statement. 
The average estimate of eight analysts surveyed by Bloomberg was for a 3.9 per cent gain. The health unit, which includes Mucinex and Nurofen painkillers, boosted sales 13 per cent, exceeding analyst estimates. Reckitt Benckiser extending its gain this year to 16 per cent.
Chief Executive Officer Rakesh Kapoor, faced with slowing growth in emerging markets such as Brazil, plans to cut costs by as much as 150 million pounds a year to widen profit margins. The program will include an unspecified number of job cuts and reductions in travel budgets. (www.esmmagazine.com)
